chufangao/CTO huggingface dataset:
Clinical trial NCT04668144: Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Official title: Pharmacodynamic and Pharmacokinetic Profiles on Switching From Cangrelor to Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet -6 (SWAP-6) Study
Acronym: SWAP-6
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 359.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-02-18
Primary completion date: 2023-02-02
Completion date: 2023-05-11
Baseline population: Patients who were randomized and received study medications
Clinical trial NCT04413253: Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease
Official title: Intracanalicular Dexamethasone Used in Conjunction With Xiidra (Lifitegrast Ophthalmic Solution) for the Treatment of Signs and Symptoms of Dry Eye Disease as Compared to Xiidra Alone
Sponsor: Eye Surgeons of Indiana (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Unable to recruit
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-01
Primary completion date: 2022-04-11
Completion date: 2022-04-11
Clinical trial NCT04531748: Selective Estrogen Modulation and Melatonin in Early COVID-19
Official title: Selective Estrogen Modulation and Melatonin in Early COVID-19
Acronym: SENTINEL
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-31
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Clinical trial NCT05168865: Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients.
Official title: Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. Randomized Controlled Study
Sponsor: Dubai Fertility Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: unexpected slow recruitment and change of center frozen embryo transfer protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-01
Primary completion date: 2024-02-01
Completion date: 2024-04-01
Clinical trial NCT03524820: Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
Official title: Cetuximab Monotherapy or Cetuximab + Chemotherapy for Third Line Rechallenge in Metastatic Colorectal Cancer, RAS+ (RAt Sarcoma Gene) Wild Type Patients, Who Were Treated With Cetuximab Chemotherapy as First Line Treatment
Sponsor: Hadassah Medical Organization (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: By Merck
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-17
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT05639192: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
Official title: A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy of Asunercept for the Treatment of Hospitalized Patients With Moderate to Severe COVID 19 Disease
Acronym: ASUCOV
Sponsor: Apogenix AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lack of patients
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-03
Primary completion date: 2023-08-18
Completion date: 2023-08-18
Clinical trial NCT04680936: Low and High Dose Dextrose Prolotherapy in the Treatment of Lateral Epicondylitis
Official title: Is Low Dose Dextrose Prolotherapy as Effective as High Dose Dextrose Prolotherapy in the Treatment of Lateral Epicondylitis?- A Double Blind- Ultrasound Guided- Randomized Controlled Study
Sponsor: Ahi Evran University Education and Research Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 75.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-01-01
Primary completion date: 2022-05-01
Completion date: 2022-05-21
Plan to share individual participant data: NO
Clinical trial NCT03506048: Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
Official title: A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study has been abandoned for lack of accrual
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-16
Primary completion date: 2021-06-24
Completion date: 2021-06-24
Limitations and caveats: Early termination of the study because of recruitment difficulties lead to insufficient data collection and analysis of primary and secondary outcome measures. Pharmaceutical company terminated study.
Clinical trial NCT04149444: A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
Official title: A Phase 2 Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
Acronym: TACTIC
Sponsor: AHS Cancer Control Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor withdrew support
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-29
Primary completion date: 2020-06-09
Completion date: 2020-06-09
Plan to share individual participant data: NO
Clinical trial NCT04343755: Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
Official title: Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection
Sponsor: Hackensack Meridian Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of eligible patients due to change in standard therapy
Enrollment: 52.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-09
Primary completion date: 2023-04-26
Completion date: 2023-04-26
Plan to share individual participant data: NO
Clinical trial NCT03338764: An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia
Official title: A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia
Sponsor: Sequential Medicine Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: no participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Clinical trial NCT02748564: Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Official title: Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study Complete
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-21
Primary completion date: 2018-10-18
Completion date: 2023-06-05
Plan to share individual participant data: NO
Clinical trial NCT04358471: Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Official title: A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Sponsor: Hemera Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The AAVCAGsCD59 asset has been transferred to Janssen Research and Development LLC
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-31
Primary completion date: 2023-07-01
Completion date: 2023-09-01
Plan to share individual participant data: NO
Clinical trial NCT04994561: VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements
Official title: Pilot Study to Test the Safety and Efficacy of Metformin, Dasatinib, Rapamycin and Nutritional Supplements (Bio-quercetin; Bio-fisetin; Glucosamine; Nicotinamide Riboside; Trans-resveratrol) in Reducing Clinical Measures of Aging in Older Adults
Sponsor: Vitality in Aging Research Group, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study was withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-30
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT02185417: Diuretic Comparison Project
Official title: CSP #597 - Diuretic Comparison Project
Acronym: DCP
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 20723.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-06-15
Primary completion date: 2022-10-15
Completion date: 2022-12-29
Baseline population: Analysis and report of baseline information according to the intention-to-treat principle. Baseline characteristics were not collected for providers.
Limitations and caveats: This trial had several important limitations:~* most patients treated with hydrochlorothiazide, including the VA population, received 12.5 to 25 mg, and only 5% in this trial had been receiving 50 mg of hydrochlorothiazide at baseline.~* only a subset of follow-up data from Medicare and NDI were available at the time of reporting.
Plan to share individual participant data: NO
IPD sharing description: There is no IPD sharing plan description
Clinical trial NCT04214860: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Official title: Phase I Study of APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Sponsor: Aprea Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 51.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-13
Primary completion date: 2022-01-14
Completion date: 2022-01-14
Plan to share individual participant data: NO
Clinical trial NCT05493293: Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
Official title: Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With Focal Onset Seizures (FOS)
Sponsor: Neurocrine Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The long-term extension study was terminated because the parent study NBI-921352-FOS2021 (NCT05159908) failed to meet its primary endpoint.
Enrollment: 82.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-11-09
Primary completion date: 2024-03-11
Completion date: 2024-03-11
Plan to share individual participant data: NO
Clinical trial NCT04624113: Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Official title: Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Ipsen bought out Epizyme
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-14
Primary completion date: 2022-08-09
Completion date: 2024-02-17
Plan to share individual participant data: NO
Clinical trial NCT03724071: Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
Official title: A Phase I/IIa Study of TG6002 (VV TK-RR-FCU1) Administered by Intravenous (IV) Infusions in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Gastro-intestinal (GI) Tumors.
Sponsor: Transgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study has been terminated after Phase I part on 23 February 2023
Enrollment: 51.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-16
Primary completion date: 2023-02-23
Completion date: 2023-02-23
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04803227: Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Official title: Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Sponsor: Histogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Unforeseeable difficulties in recruiting patients. There were no reported serious adverse events.
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-11
Primary completion date: 2021-05-28
Completion date: 2021-05-28
Plan to share individual participant data: NO
Clinical trial NCT03759366: A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Official title: An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-21
Primary completion date: 2022-01-06
Completion date: 2023-11-06
Baseline population: Full analysis set included all participants who received at least 1 dose of eculizumab.
Plan to share individual participant data: NO
Clinical trial NCT03117634: An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
Official title: An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen
Sponsor: Singapore National Eye Centre (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 54.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-01
Primary completion date: 2020-06-30
Completion date: 2021-01-31
Limitations and caveats: More participants in the personalised group(3:1)increased the power to detect outcomes. 52 week study duration may not fully demonstrate the advantages of a TNE regimen,PL closure. Study not powered to detect the difference in PL closure at month 3.
Plan to share individual participant data: NO
Clinical trial NCT05274269: Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
Official title: A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 307.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-09
Primary completion date: 2023-07-05
Completion date: 2023-07-05
Baseline population: All participants who received at least one dose of the study drug were included in the baseline analysis.
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT05112536: Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Official title: A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)
Sponsor: G1 Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-03
Primary completion date: 2022-10-31
Completion date: 2023-03-13
Limitations and caveats: A limitation of this study was the small number of participants.
Plan to share individual participant data: NO
Clinical trial NCT04675242: Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
Official title: Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension, 0.1% QD for the Treatment of Acute Exacerbations of Blepharitis (Mississippi)
Acronym: Mississippi
Sponsor: Nicox Ophthalmics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 224.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-14
Primary completion date: 2021-06-16
Completion date: 2021-06-30
Baseline population: Study Eye
Plan to share individual participant data: NO
Clinical trial NCT04701190: Different Noradrenaline Protocols in Post Spinal Hypotension in CS
Official title: Comparison of Different Noradrenaline Protocols to Prevent Post Spinal Hypotension During Elective Caesarean Delivery: A Randomised, Double-blind Clinical Trial
Sponsor: Ankara University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 180.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-02-01
Primary completion date: 2021-12-15
Completion date: 2021-12-15
Plan to share individual participant data: NO
Clinical trial NCT03239080: Effect of Denosumab in Erosion Healing in RA
Official title: Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT
Sponsor: Chinese University of Hong Kong (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 110.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-19
Primary completion date: 2020-05-24
Completion date: 2020-05-24
Clinical trial NCT04155099: Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
Official title: Assessment of Cognitive Ability and the Intestinal Microbiome in Individuals With Liver Disease Before and After Investigational Microbiota Restoration Therapeutic
Sponsor: Ochsner Health System (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Unable to recruit participants
Enrollment: 5.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-01
Primary completion date: 2023-07-30
Completion date: 2023-07-30
Plan to share individual participant data: NO
Clinical trial NCT05234606: A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Official title: A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Subjects With Advanced Solid Tumors Associated With Nectin-4 Expression
Sponsor: Silverback Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor decision based on strategic re-alignment
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-03-31
Primary completion date: 2022-03-31
Completion date: 2022-03-31
Plan to share individual participant data: NO
Clinical trial NCT03712787: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
Official title: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956).
Enrollment: 364.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-03-22
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Baseline population: Safety Data Set: All participants who received at least 1 dose of study drug in M15-570.
Limitations and caveats: Study M15-570 was discontinued because of lack of efficacy in the parent study (Study M15-566) and 2) the tilavonemab development program was discontinued.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing, please refer to the link below.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04502667: Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19
Official title: Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19: Open Controlled Clinical Trial
Acronym: COVID-19
Sponsor: Coordinación de Investigación en Salud, Mexico (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 45.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-15
Primary completion date: 2021-03-31
Completion date: 2021-09-15
Plan to share individual participant data: NO
Clinical trial NCT03644459: Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
Official title: Phase I Study of the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 With Blocking of Autocrine Loops VEGFR1/2/3
Sponsor: Lynkcell Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Unable to recruit individuals for the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-03
Primary completion date: 2020-06-30
Completion date: 2020-08-31
Clinical trial NCT03782376: A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
Official title: A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
Acronym: POWER
Sponsor: Janssen-Cilag Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 215.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-20
Primary completion date: 2022-08-19
Completion date: 2023-01-10
Limitations and caveats: Some exploratory endpoints including endoscopic assessments for baseline and Week 16, and clinical data for 24 weeks are not reported in this summary and will be included in the manuscript.
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\\transparency.~As noted on this site, requests for access to the study data can be submitted through Yale open and Access (YODA) Project site at yoda.yale.edu